Literature DB >> 19409547

Assay reproducibility and within-person variation of Müllerian inhibiting substance.

Joanne F Dorgan1, Cynthia S Spittle, Brian L Egleston, Christiana M Shaw, Lisa L Kahle, Louise A Brinton.   

Abstract

OBJECTIVES: To assess reproducibility of a commercial müllerian inhibiting substance (MIS) assay and evaluate within-person variation in serum MIS levels.
DESIGN: Assay reproducibility was evaluated by measuring MIS in multiple serum aliquots from the same blood collection. Within-person variation was assessed by measuring MIS in serum collected twice from the same individuals.
SETTING: Cancer Prevention Biomarker and Genotyping Facility, fox Chase Cancer Center, Philadelphia, Pennsylvania. PATIENT(S): Assay reproducibility was evaluated using serum from five volunteers with regular menstrual cycles. Within-person variation was evaluated in serum from 20 premenopausal women who donated blood twice at least 1 year apart. INTERVENTION(S): For both studies, samples were randomly ordered in batches and laboratory personnel were blinded to which aliquots were from the same subject. MAIN OUTCOME MEASURE(S): The MIS was measured by ELISA. RESULT(S): Within- and between-batch coefficients of variation (CVs) of the assay were 7.9% and 12.3%, respectively. After deleting one subject with extreme values, these CVs decreased to 7.6% and 7.7%, respectively. Within- and between-subject variance in MIS measurements were 2.19 and 0.31, respectively, and the intraclass correlation coefficient was 0.88 (95% confidence interval .77-.98). CONCLUSION(S): The MIS serum concentration is relatively stable over 1 year in premenopausal women and can be measured with good reproducibility using a commercial kit. Copyright (c) 2010 American Society for Reproductive Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409547      PMCID: PMC2876207          DOI: 10.1016/j.fertnstert.2009.03.032

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  16 in total

1.  Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation.

Authors:  Wouter J K Hehenkamp; Caspar W N Looman; Axel P N Themmen; Frank H de Jong; E R Te Velde; Frank J M Broekmans
Journal:  J Clin Endocrinol Metab       Date:  2006-06-27       Impact factor: 5.958

Review 2.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

3.  Antimüllerian hormone serum levels: a putative marker for ovarian aging.

Authors:  Annemarie de Vet; Joop S E Laven; Frank H de Jong; Axel P N Themmen; Bart C J M Fauser
Journal:  Fertil Steril       Date:  2002-02       Impact factor: 7.329

Review 4.  The Anti-Mullerian hormone and ovarian cancer.

Authors:  Antonio La Marca; Annibale Volpe
Journal:  Hum Reprod Update       Date:  2007-01-09       Impact factor: 15.610

5.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

6.  Serum anti-Mullerian hormone throughout the human menstrual cycle.

Authors:  A La Marca; G Stabile; A Carducci Artenisio; A Volpe
Journal:  Hum Reprod       Date:  2006-08-21       Impact factor: 6.918

Review 7.  Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications.

Authors:  J Teixeira; S Maheswaran; P K Donahoe
Journal:  Endocr Rev       Date:  2001-10       Impact factor: 19.871

8.  Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

Authors:  Pascal Pigny; Emilie Merlen; Yann Robert; Christine Cortet-Rudelli; Christine Decanter; Sophie Jonard; Didier Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

9.  Clinical significance of serum concentration of anti-Müllerian hormone in obese women with polycystic ovary syndrome.

Authors:  Samir El-Halawaty; Ahmed Rizk; Manal Kamal; Mona Aboulhassan; Heba Al-Sawah; Olfat Noah; Hesham Al-Inany
Journal:  Reprod Biomed Online       Date:  2007-11       Impact factor: 3.828

10.  Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.

Authors:  Joop S E Laven; Annemarie G M G J Mulders; Jenny A Visser; Axel P Themmen; Frank H De Jong; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

View more
  13 in total

1.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

2.  Serum antimüllerian hormone in healthy premenopausal women.

Authors:  Christiana M Shaw; Frank Z Stanczyk; Brian L Egleston; L L Kahle; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

3.  Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.

Authors:  Sarah R Irvin; Elisabete Weiderpass; Frank Z Stanczyk; Louise A Brinton; Britton Trabert; Hilde Langseth; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

4.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

5.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

6.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.

Authors:  A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-09       Impact factor: 4.254

7.  Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome.

Authors:  Sergio Parco; Caterina Novelli; Fulvia Vascotto; Tanja Princi
Journal:  Int J Gen Med       Date:  2011-11-02

8.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

9.  Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women.

Authors:  Tess V Clendenen; Wenzhen Ge; Karen L Koenig; Yelena Afanasyeva; Claudia Agnoli; Elizabeth Bertone-Johnson; Louise A Brinton; Farbod Darvishian; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

Review 10.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.